United States:
Episode 50: Pharma Pricing Climate In Washington
24 February 2020
Buchanan Ingersoll & Rooney PC
To print this article, all you need is to be registered or login on Mondaq.com.
Mike Strazzella, head of federal government relations for
Buchanan Ingersoll & Rooney, talks about pricing issues in the
pharmaceutical industry, the challenges he encounters, and what he
believes needs to change in the industry going forward.
You can listen and/or download the episode on SoundCloud,
or directly through iTunes, GooglePlay, Stitcher, and Overcast.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...